Publicacions en col·laboració amb investigadors/es de Academic Medical Center (18)

2024

  1. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

  2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  3. Correction to: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (Blood Cancer Journal, (2024), 14, 1, (24), 10.1038/s41408-023-00966-9)

    Blood Cancer Journal

  4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  5. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

    Blood Cancer Journal, Vol. 14, Núm. 1

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2022

  1. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

2021

  1. The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders

    HemaSphere, Vol. 5, Núm. 10, pp. E643

2020

  1. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis

    The Lancet Haematology, Vol. 7, Núm. 10, pp. e746-e755

  2. Performance of 18F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis

    Thrombosis Research, Vol. 194, pp. 153-157

  3. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 8, pp. 1940-1951

2019

  1. Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis

    Thrombosis Research, Vol. 176, pp. 79-84

2017

  1. Screening for cancer in patients with unprovoked venous thromboembolism: Protocol for a systematic review and individual patient data meta-analysis

    BMJ Open, Vol. 7, Núm. 6

  2. Screening for occult cancer in patients with unprovoked venous thromboembolism

    Annals of Internal Medicine, Vol. 167, Núm. 6, pp. 410-417

2015

  1. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar

    Journal of the American College of Cardiology, Vol. 65, Núm. 19, pp. 2057-2066

2013

  1. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer

    Journal of Thrombosis and Haemostasis, Vol. 11, Núm. 1, pp. 71-80

  2. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    Journal of Thrombosis and Haemostasis, Vol. 11, Núm. 1, pp. 56-70

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051